Research map: Treatment of severe hypertriglyceridemia: a new era dawns

Back to the article

Papers in this map

  1. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial · Ania M. Jastreboff · 2023 · 1110 citations · Cited by this paper
  2. Application of Theranostics in Thyroid Cancer Management · 2026 · Related
  3. Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society · Henry N. Ginsberg · 2021 · 972 citations · Cited by this paper
  4. Medical treatments for obesity: what does the future have in store? · 2026 · Related
  5. Acquired and Inherited Lipodystrophies · Abhimanyu Garg · 2004 · 948 citations · Cited by this paper
  6. Inter-individual variation in gastric emptying is related to GLP-1 response to intraduodenal glucose exposure in health · 2026 · Related
  7. New insights into acute pancreatitis · Peter Junwoo Lee · 2019 · 941 citations · Cited by this paper
  8. Low serum testosterone concentrations predict incident frailty in men with HIV · 2026 · Related
  9. Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk · Aruna D. Pradhan · 2022 · 748 citations · Cited by this paper
  10. Impairment in the hypothalamic–pituitary–gonadal axis in males with medullary thyroid carcinoma treated with selpercatinib · 2026 · Related
  11. A Null Mutation in Human APOC3 Confers a Favorable Plasma Lipid Profile and Apparent Cardioprotection · Toni I. Pollin · 2008 · 697 citations · Cited by this paper
  12. Is the diagnosis of Cushing disease moving beyond bilateral inferior petrosal sinus sampling? · 2026 · Related
  13. 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias · François Mach · 2025 · 601 citations · Cited by this paper
  14. Prospective evaluation of the effect of stopping estrogen-containing contraceptives on serum CBG and cortisol levels · 2026 · Related
  15. Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia · Daniel Gaudet · 2015 · 537 citations · Cited by this paper
  16. Consensus on Biomarker Utility for ACTH-Dependent Cushing’s Syndrome: A Pituitary Society Modified Delphi Panel · 2026 · Related
  17. Inactivating Variants in ANGPTL4 and Risk of Coronary Artery Disease · Frederick E. Dewey · 2016 · 521 citations · Cited by this paper
  18. Melanocortin-4 receptor regulation of endocrine axes and clinical effects of setmelanotide · 2026 · Related
  19. Population-based resequencing of ANGPTL4 uncovers variations that reduce triglycerides and increase HDL · Stefano Romeo · 2007 · 517 citations · Cited by this paper
  20. New and Emerging Therapeutic Targets for ApoB-Containing Particles Lowering. · 2025 · Related
  21. Coding Variation in ANGPTL4, LPL, and SVEP1 and the Risk of Coronary Disease · Myocardial Infarction Genetics and CARDIoGRAM Exome Consortia Investigators · 2016 · 508 citations · Cited by this paper
  22. Targeting APOC3 in the Familial Chylomicronemia Syndrome · Daniel Gaudet · 2014 · 499 citations · Cited by this paper
  23. Glucagonlike Peptide 1–Based Therapies and Risk of Hospitalization for Acute Pancreatitis in Type 2 Diabetes Mellitus · Sonal Singh · 2013 · 463 citations · Cited by this paper
  24. Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial · Daniel Gaudet · 2012 · 407 citations · Cited by this paper
  25. Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome · Erik S.G. Stroes · 2024 · 262 citations · Cited by this paper
  26. Inhibition of Angiopoietin-Like Protein 3 With a Monoclonal Antibody Reduces Triglycerides in Hypertriglyceridemia · Zahid Ahmad · 2019 · 251 citations · Cited by this paper
  27. Lipoprotein Lipase and Its Regulators: An Unfolding Story · Shuangcheng Alivia Wu · 2020 · 224 citations · Cited by this paper
  28. Severe hypertriglyceridemia is primarily polygenic · Jacqueline S. Dron · 2018 · 222 citations · Cited by this paper
  29. Zodasiran, an RNAi Therapeutic Targeting ANGPTL3, for Mixed Hyperlipidemia · Robert S. Rosenson · 2024 · 211 citations · Cited by this paper
  30. Angiopoietin-like protein 3 governs LDL-cholesterol levels through endothelial lipase-dependent VLDL clearance · Rene C. Adam · 2020 · 208 citations · Cited by this paper
  31. Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia · Christie Mitchell Ballantyne · 2024 · 207 citations · Cited by this paper
  32. Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statement · Robert Alexander Hegele · 2019 · 205 citations · Cited by this paper
  33. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial · Shweta Urva · 2022 · 202 citations · Cited by this paper
  34. Apolipoprotein C-III: From Pathophysiology to Pharmacology · Giuseppe Danilo Norata · 2015 · 187 citations · Cited by this paper
  35. Gene therapy for lipoprotein lipase deficiency · Daniel Gaudet · 2012 · 179 citations · Cited by this paper
  36. Plozasiran for Managing Persistent Chylomicronemia and Pancreatitis Risk · Gerald F. Watts · 2024 · 170 citations · Cited by this paper
  37. Plozasiran (ARO-APOC3) for Severe Hypertriglyceridemia · Daniel Gaudet · 2024 · 168 citations · Cited by this paper
  38. Effect of Alipogene Tiparvovec (AAV1-LPL S447X ) on Postprandial Chylomicron Metabolism in Lipoprotein Lipase-Deficient Patients · André C. Carpentier · 2012 · 166 citations · Cited by this paper
  39. Glucagon‐like peptide‐1 receptor agonists and risk of acute pancreatitis in patients with type 2 diabetes · Heidi Storgaard · 2017 · 153 citations · Cited by this paper

Source: OpenAlex (CC0)